AbbVie, Enbridge, Realty Income: Top Dividend Stocks for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ABBV?
Source: Fool
- AbbVie's Strong Returns: AbbVie (ABBV), a 'Dividend King' with 50 consecutive years of dividend increases, currently offers a 3.1% yield; despite rising share prices, its P/E ratio remains below 16, indicating strong value and potential for continued growth and shareholder returns.
- Enbridge's Growth Potential: Enbridge (ENB) boasts a 6.1% dividend yield and has increased dividends for 30 years, with projected growth opportunities of $50 billion by 2030, particularly in its gas transmission business to meet rising demand from data centers.
- Realty Income's Diversified Investments: Realty Income (O) attracts investors with a 5.5% yield and a record of 112 consecutive dividend increases, owning 15,542 properties across 92 industries, showcasing resilience and growth potential amid economic fluctuations.
- Market Opportunities Driven by Data Centers: The surge in data center construction benefits AbbVie, Enbridge, and Realty Income, highlighting their sustained investment appeal through 2026 and beyond due to increasing demand for natural gas and real estate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 223.260
Low
218.00
Averages
253.26
High
289.00
Current: 223.260
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
High Dividend ETFs Offer Stability for Investors
- Risk Assessment: The recent volatility in silver and gold prices has increased investor risk, making traditional safe-haven assets less ideal for risk-averse investors.
- ETF Investment Benefits: The iShares Core High Dividend ETF focuses on high-quality dividend stocks, holding around 75 selectively chosen stocks to ensure sustainable payouts, thereby reducing investment risk.
- Yield and Fee Analysis: This ETF offers an annual yield of approximately 3%, nearly three times that of the S&P 500, with an expense ratio of just 0.08%, resulting in only $8 in fees per year on a $10,000 investment, significantly enhancing net returns.
- Long-Term Investment Strategy: With its combination of high yield, low fees, and quality dividend stocks, the iShares Core High Dividend ETF is an ideal choice for long-term investors looking to mitigate market risks, applicable not only in the current environment but also for future investment strategies.
See More
Gold and Silver Investment Risks Increase Amid Volatility
- Increased Investment Risks: Recent volatility in gold and silver prices has heightened risks for investors, particularly for risk-averse individuals, as the increased speculation surrounding these traditionally safe assets complicates investment decisions.
- ETF Investment Advantages: Investors are encouraged to consider high-dividend exchange-traded funds (ETFs) like the iShares Core High Dividend ETF (HDV), which offers a yield of approximately 3%, significantly higher than the S&P 500's 1.1%, and features a low expense ratio of just 0.08%, ensuring that long-term returns are not eroded by high fees.
- Quality Stock Portfolio: The iShares ETF comprises around 75 carefully selected stocks, including high-quality companies like ExxonMobil, AbbVie, and Coca-Cola, which have strong financial health and can provide sustainable dividends, thereby reducing investment risk.
- Long-Term Investment Strategy: In the current market environment, opting for low-fee, high-yield ETFs like the iShares Core High Dividend ETF can help investors achieve a stable income stream amidst uncertainty, making it suitable for long-term investors looking to mitigate risk.
See More
Next-Gen CNS Assets Attract Investor Interest
- Significant Drug Efficacy: Novel serotonergic agonists (NSAs) activate specific serotonin receptors to produce faster and more meaningful results than traditional antidepressants, positioning them to capture a significant share of the $50-60 billion depression and anxiety treatment market, thereby enhancing patient treatment experiences and outcomes.
- Massive Market Potential: The global neuropsychiatric drug market is projected to exceed $150 billion by the end of the decade, and as awareness and acceptance of new serotonin-based therapies increase, NSAs are poised to secure a meaningful slice of this market, driving long-term growth for the company.
- Leadership Transition: Helus Pharma has appointed Michael Cola as CEO, whose extensive experience in neuroscience and global commercialization is expected to accelerate the development of next-generation mental health therapies and expedite the release of clinical data and market entry.
- Intellectual Property Strategy: Helus Pharma has filed over 350 patent applications globally, with more than 100 patents granted, and as the company transitions from early clinical development to later-stage execution, its robust intellectual property portfolio will provide a competitive edge and support future commercialization efforts.
See More
Next-Gen CNS Assets Attract Investor Interest
- Market Potential: The global market for depression and anxiety treatments is projected to exceed $50-60 billion annually, while the broader neuropsychiatric drug market is expected to surpass $150 billion by the end of the decade, highlighting the significant potential of novel serotonergic agonists (NSAs) in the rapidly growing mental health sector.
- Clinical Data Impact: NSAs are designed to act faster than traditional antidepressants, effectively treating complex conditions such as depression, PTSD, anxiety, and addiction, which is anticipated to significantly improve patient outcomes and attract increased investor interest.
- Leadership Change: Helus Pharma has appointed Michael Cola as CEO, who brings over 30 years of experience in neuroscience and specialty pharmaceuticals, expected to drive the company towards key clinical milestones, including the upcoming Phase 2 data for HLP004 and Phase 3 data for HLP003.
- Intellectual Property Strategy: Helus Pharma has filed over 350 patent applications and secured more than 100 patents across its multi-asset pipeline, demonstrating its capability in global intellectual property protection, which enhances its competitive position and long-term growth potential in the market.
See More
CVS Expands Biosimilar Access to Lower Drug Costs
- Biosimilar Introduction: CVS Health announced that starting April 1, 2026, it will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide products Bonsity and Tymlos, to its major national commercial formularies, providing patients with more cost-effective treatment options.
- Significant Cost Savings: Ed DeVaney, President of CVS Caremark, stated that the company has generated $1.5 billion in gross savings for customers and members by replacing Humira with biosimilars, demonstrating the value of formulary tools in driving competition.
- High Transition Success Rate: CVS Caremark reported that 96% of its clients using Humira successfully transitioned to a biosimilar, indicating effective support and guidance provided during the medication switch process.
- Formulary Update Process: CVS Specialty proactively contacts prescribers and patients during formulary changes to explain updates and guide them through the transition, ensuring patients receive timely access to necessary treatments.
See More
Bristol Myers Squibb Reports Strong Q4 Results and Positive 2026 Outlook
- Strong Earnings Report: Bristol Myers Squibb reported fourth-quarter revenue of $12.5 billion, a 1% increase year-over-year, surpassing the $12.28 billion expected by analysts, which enhances investor confidence in the company's stability in drug sales.
- Earnings Beat Expectations: Although earnings per share fell 25% year-over-year to $1.26, it still exceeded estimates of $1.12, reflecting effective cost control and margin improvement strategies that further solidify its market position.
- Optimistic 2026 Outlook: The company forecasts revenue between $46 billion and $47.5 billion for 2026, exceeding the $44.16 billion expected by the market, indicating confidence in future growth, particularly driven by the new drug Cobenfy.
- Cost-Saving Commitment: Bristol Myers is committed to achieving approximately $1 billion in cost savings in 2025 and plans to save another $1 billion over the next two years, which will enhance the company's profitability and competitive edge in the market.
See More
High Dividend ETFs Offer Stability for Investors
- Risk Assessment: The recent volatility in silver and gold prices has increased investor risk, making traditional safe-haven assets less ideal for risk-averse investors.
- ETF Investment Benefits: The iShares Core High Dividend ETF focuses on high-quality dividend stocks, holding around 75 selectively chosen stocks to ensure sustainable payouts, thereby reducing investment risk.
- Yield and Fee Analysis: This ETF offers an annual yield of approximately 3%, nearly three times that of the S&P 500, with an expense ratio of just 0.08%, resulting in only $8 in fees per year on a $10,000 investment, significantly enhancing net returns.
- Long-Term Investment Strategy: With its combination of high yield, low fees, and quality dividend stocks, the iShares Core High Dividend ETF is an ideal choice for long-term investors looking to mitigate market risks, applicable not only in the current environment but also for future investment strategies.
See More
Gold and Silver Investment Risks Increase Amid Volatility
- Increased Investment Risks: Recent volatility in gold and silver prices has heightened risks for investors, particularly for risk-averse individuals, as the increased speculation surrounding these traditionally safe assets complicates investment decisions.
- ETF Investment Advantages: Investors are encouraged to consider high-dividend exchange-traded funds (ETFs) like the iShares Core High Dividend ETF (HDV), which offers a yield of approximately 3%, significantly higher than the S&P 500's 1.1%, and features a low expense ratio of just 0.08%, ensuring that long-term returns are not eroded by high fees.
- Quality Stock Portfolio: The iShares ETF comprises around 75 carefully selected stocks, including high-quality companies like ExxonMobil, AbbVie, and Coca-Cola, which have strong financial health and can provide sustainable dividends, thereby reducing investment risk.
- Long-Term Investment Strategy: In the current market environment, opting for low-fee, high-yield ETFs like the iShares Core High Dividend ETF can help investors achieve a stable income stream amidst uncertainty, making it suitable for long-term investors looking to mitigate risk.
See More
Next-Gen CNS Assets Attract Investor Interest
- Significant Drug Efficacy: Novel serotonergic agonists (NSAs) activate specific serotonin receptors to produce faster and more meaningful results than traditional antidepressants, positioning them to capture a significant share of the $50-60 billion depression and anxiety treatment market, thereby enhancing patient treatment experiences and outcomes.
- Massive Market Potential: The global neuropsychiatric drug market is projected to exceed $150 billion by the end of the decade, and as awareness and acceptance of new serotonin-based therapies increase, NSAs are poised to secure a meaningful slice of this market, driving long-term growth for the company.
- Leadership Transition: Helus Pharma has appointed Michael Cola as CEO, whose extensive experience in neuroscience and global commercialization is expected to accelerate the development of next-generation mental health therapies and expedite the release of clinical data and market entry.
- Intellectual Property Strategy: Helus Pharma has filed over 350 patent applications globally, with more than 100 patents granted, and as the company transitions from early clinical development to later-stage execution, its robust intellectual property portfolio will provide a competitive edge and support future commercialization efforts.
See More
Next-Gen CNS Assets Attract Investor Interest
- Market Potential: The global market for depression and anxiety treatments is projected to exceed $50-60 billion annually, while the broader neuropsychiatric drug market is expected to surpass $150 billion by the end of the decade, highlighting the significant potential of novel serotonergic agonists (NSAs) in the rapidly growing mental health sector.
- Clinical Data Impact: NSAs are designed to act faster than traditional antidepressants, effectively treating complex conditions such as depression, PTSD, anxiety, and addiction, which is anticipated to significantly improve patient outcomes and attract increased investor interest.
- Leadership Change: Helus Pharma has appointed Michael Cola as CEO, who brings over 30 years of experience in neuroscience and specialty pharmaceuticals, expected to drive the company towards key clinical milestones, including the upcoming Phase 2 data for HLP004 and Phase 3 data for HLP003.
- Intellectual Property Strategy: Helus Pharma has filed over 350 patent applications and secured more than 100 patents across its multi-asset pipeline, demonstrating its capability in global intellectual property protection, which enhances its competitive position and long-term growth potential in the market.
See More
CVS Expands Biosimilar Access to Lower Drug Costs
- Biosimilar Introduction: CVS Health announced that starting April 1, 2026, it will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide products Bonsity and Tymlos, to its major national commercial formularies, providing patients with more cost-effective treatment options.
- Significant Cost Savings: Ed DeVaney, President of CVS Caremark, stated that the company has generated $1.5 billion in gross savings for customers and members by replacing Humira with biosimilars, demonstrating the value of formulary tools in driving competition.
- High Transition Success Rate: CVS Caremark reported that 96% of its clients using Humira successfully transitioned to a biosimilar, indicating effective support and guidance provided during the medication switch process.
- Formulary Update Process: CVS Specialty proactively contacts prescribers and patients during formulary changes to explain updates and guide them through the transition, ensuring patients receive timely access to necessary treatments.
See More
Bristol Myers Squibb Reports Strong Q4 Results and Positive 2026 Outlook
- Strong Earnings Report: Bristol Myers Squibb reported fourth-quarter revenue of $12.5 billion, a 1% increase year-over-year, surpassing the $12.28 billion expected by analysts, which enhances investor confidence in the company's stability in drug sales.
- Earnings Beat Expectations: Although earnings per share fell 25% year-over-year to $1.26, it still exceeded estimates of $1.12, reflecting effective cost control and margin improvement strategies that further solidify its market position.
- Optimistic 2026 Outlook: The company forecasts revenue between $46 billion and $47.5 billion for 2026, exceeding the $44.16 billion expected by the market, indicating confidence in future growth, particularly driven by the new drug Cobenfy.
- Cost-Saving Commitment: Bristol Myers is committed to achieving approximately $1 billion in cost savings in 2025 and plans to save another $1 billion over the next two years, which will enhance the company's profitability and competitive edge in the market.
See More
